Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Imaging of Residual Prostate Cancer During Prostatectomy Using ProstaFluor®, a Prostate-Specific Membrane Antigen (PSMA)-Targeted Fluorescent Agent FDA Trial

NCT01173146 is registered in ClinicalTrials.gov with Spectros Corporation as lead sponsor.

NCT NCT01173146
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01173146 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Imaging of Residual Prostate Cancer During Prostatectomy Using ProstaFluor®, a Prostate-Specific Membrane Antigen (PSMA)-Targeted Fluorescent Agent FDA Trial
Lead sponsor
Spectros Corporation
Phase
Observational
Overall status
Withdrawn
Start date
December 31, 2011
Completion date
June 30, 2015
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer